Simplify Logo
eMed

eMed

AI-driven platform for employer GLP-1 management

Manager – RFP Strategy - Enterprise Solutions

Full-TimeUpdated on 9/15/2026
No salary listed
Mid, Senior, Expert
Miami, FL, USA
In Person

About the job

Requirements
  • Approximately 6-15 years of relevant professional experience.
  • Significant experience working with self-funded employer health plans.
  • Demonstrated understanding of both medical and pharmacy benefits.
  • Experience in employee benefits brokerage, benefits consulting, pharmacy consulting, a pharmacy benefit manager, a health plan, employer healthcare solutions, or a healthcare point solution.
  • Significant experience completing or managing complex requests for proposals, requests for information, consultant evaluations, or formal healthcare procurements.
  • Strong understanding of how major benefits consulting organizations evaluate vendors.
  • Exceptional written communication skills.
  • Strong project management capabilities with experience coordinating numerous subject-matter experts under tight deadlines.
  • Strong analytical and financial capabilities.
  • Ability to understand complex business requirements and translate them into differentiated responses.
  • Advanced Microsoft Excel, PowerPoint, and Microsoft Office skills.
Responsibilities
  • Lead end-to-end responses to complex requests for proposals, requests for information, consultant evaluations, and other formal procurement processes.
  • Review each procurement to identify underlying business requirements, evaluation criteria, competitive dynamics, risks, and strategic opportunities.
  • Develop an overall response strategy rather than treating a request for proposal as a series of independent questions.
  • Translate detailed request-for-proposal requirements into clear workstreams, responsibilities, deadlines, and internal deliverables.
  • Determine whether to provide a standard response, customized solution, alternative recommendation, or additional context.
  • Ensure responses present a coherent story about the clinical model, pharmacy strategy, economics, member experience, implementation capabilities, reporting, and outcomes.
  • Maintain compliance with procurement requirements, deadlines, formatting requirements, attachments, certifications, and submission instructions.
  • Interpret questions involving self-funded medical plans, pharmacy benefit managers, pharmacy contracting, clinical programs, eligibility, benefit administration, plan design, implementation, reporting, and healthcare economics.
  • Evaluate requirements involving pharmacy benefit manager integration, pharmacy carve-outs, formulary strategy, prior authorization, utilization management, specialty and high-cost medications, GLP-1 management, member eligibility, accumulator integration, claims and pharmacy data, clinical protocols, member engagement, performance guarantees, implementation, reporting and outcomes, financial guarantees, and pricing.
  • Identify conflicts between requested approaches and the company model and develop alternatives or exceptions.
  • Recognize contractual, financial, clinical, operational, and implementation risks within procurement requirements.
  • Partner with Finance and Commercial leadership to develop pricing and financial responses.
  • Build or review analyses involving population size, utilization, prescription costs, member contributions, program fees, pharmacy savings, medical cost avoidance, and total cost of care.
  • Analyze prospect data to determine the financial implications of the proposed solution.
  • Support savings methodologies, return-on-investment projections, performance guarantees, and financial commitments.
  • Ensure financial responses across technical questionnaires, pricing exhibits, proposals, and contractual materials remain internally consistent.
  • Challenge assumptions when financial or operational commitments create unnecessary risk.
  • Coordinate contributions from Sales, Partnerships, Clinical, Product, Engineering, Finance, Legal, Compliance, Operations, Implementation, Client Success, Security, and other stakeholders.
  • Translate highly technical subject-matter responses into concise, persuasive, client-ready language.
  • Drive internal timelines and hold contributors accountable for deliverables.
  • Escalate critical decisions and unresolved issues early enough for leadership decisions.
  • Conduct final quality-control reviews for accuracy, consistency, responsiveness, and strategic alignment.
  • Prepare executives and Sales leaders for finalist meetings and consultant presentations.
  • Develop anticipated questions, competitive objections, financial talking points, and supporting materials.
  • Participate in strategic finalist discussions when benefits or pharmacy expertise is needed.
  • Conduct post-request-for-proposal reviews to identify outcomes, competitive themes, and improvements to response strategy.
  • Establish request-for-proposal governance, workflow, intake requirements, timelines, and service-level expectations.
  • Build and maintain a centralized library of validated responses.
  • Develop reusable content while keeping strategic responses customized to the opportunity.
  • Establish subject-matter ownership for major categories of request-for-proposal content.
  • Develop processes for version control, approvals, accuracy, and response maintenance.
  • Track recurring questions and identify needs for stronger evidence, documentation, case studies, or product capabilities.
  • Train and mentor future request-for-proposal team members.
  • Over time, assume responsibility for managing the request-for-proposal response organization.
Desired Qualifications
  • Experience working for a national or regional benefits consulting or brokerage organization such as Aon, Mercer, WTW, Lockton, Gallagher, USI, Brown & Brown, HUB, OneDigital, Alliant, or a comparable organization.
  • Experience participating in pharmacy benefit manager, pharmacy, point-solution, disease-management, or healthcare vendor procurements.
  • Experience on the consultant side of request-for-proposal evaluations.
  • Direct experience with pharmacy benefit managers, pharmacy carve-outs, specialty pharmacy, GLP-1 management, or employer pharmacy strategies.
  • Familiarity with complex public-sector or government healthcare procurements.
  • Experience developing financial exhibits, pricing responses, and performance guarantees.
  • Experience supporting enterprise sales organizations without personally carrying a sales quota.

About the company

eMed operates a digital health platform that enables employer-sponsored GLP-1 weight-management programs by providing remote diagnostics, clinician-prescribed medications, and adherence coaching. Its Empathetic AI engages members, tracks biomarkers, and coordinates medical oversight with medication access and coaching under a subscription-based capitation model that covers population health management. Unlike typical programs, it tightly links access to meds with ongoing adherence through an agentic AI and structured clinical support, while shifting financial risk to employers. Its goal is to reduce health costs for employers and payers while delivering meaningful weight-management and chronic-care improvements at scale.

Company Size

201-500

Company Stage

Series A

Total Funding

$200M

Headquarters

Miami, Florida

Founded

2020

Get referred to eMed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CVS Caremark partnership opened employer-subsidized GLP-1 access in February 2026.
  • Tom Brady's January 2026 role keeps eMed visible to employers and workers.
  • March 2026 capital funds a capitated model, expanding enterprise sales capacity.

What critics are saying

  • Hims, Ro, CVS Caremark, and Alight compress eMed's pricing power immediately.
  • If Novo Nordisk and Eli Lilly lower GLP-1 list prices, eMed's savings story collapses.
  • If employers treat GLP-1s as a commodity benefit, eMed becomes a thin referral layer.

What makes eMed unique

  • March 26, 2026 funding valued eMed above $2 billion, signaling category leadership.
  • August 11, 2026 Alight added eMed to its employer GLP-1 partner network.
  • eMed's Empathetic AI pairs remote diagnostics, prescribing, and adherence coaching in one workflow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Training Programs

Meal Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

-1%

2 year growth

0%
HealthTech HotSpot
Aug 11th, 2026
Alight and eMed join forces to expand access to GLP-1 therapies for employers, advancing population and workforce health.

Alight and eMed join forces to expand access to GLP-1 therapies for employers, advancing population and workforce health. DEERFIELD, Ill.-(BUSINESS WIRE)-Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth and leave solutions, today announced the addition of eMed Population Health, Inc., a platform for employer-sponsored preventative health management, to the Alight Partner Network. The collaboration will enhance employer-sponsored access to GLP-1 therapies and give organizations a scalable way to support eligible employees, improve adherence to treatment and address the cost and complexity of weight management benefits. The groundswell of interest in GLP-1 medications among the general population has soared in recent years - 11% of U.S. adults now take GLP-1 medications for weight loss, up from 3% in 2024, according to Gallup's National Health and Well-Being Index. As demand for obesity and chronic condition management continues to rise, employers are seeking solutions that foster long-term workforce health while helping manage healthcare costs. By adding eMed to its Partner Network, Alight is expanding its health ecosystem with an industry-leading, flexible, outcomes-focused GLP-1 solution designed to support employers across a range of workforce health goals, benefits strategies and coverage approaches. Through a connected experience that includes clinical evaluation, treatment access, adherence support and ongoing engagement, organizations can provide eligible employees with personalized care, regardless of their coverage needs, while gaining greater visibility into utilization and outcomes. "Employers are looking for smarter, more sustainable ways to address rising healthcare costs while improving outcomes for their people," said Jessica Borchik, SVP, Partner Strategy and Sales at Alight. "By welcoming eMed into our Partner Network, we're expanding access to a clinically rigorous, outcomes-focused approach to GLP-1 management that helps organizations support employee health while maintaining cost control." The collaboration reflects a shared commitment to helping employers, including Fortune 500 companies already supported by Alight, implement GLP-1 programs that align with their unique needs while improving health outcomes and managing costs. "We're at a pivotal moment in healthcare where employers have an opportunity to fundamentally change the trajectory of population health and chronic diseases," said Greg Page, SVP Partnerships & Strategy at eMed. "By partnering with Alight, we're combining access and accountability in a way that helps organizations improve employee health, manage costs, and realize the full promise of GLP-1 therapies." Together, Alight and eMed will provide employers with a scalable way to manage utilization, improve adherence and reduce avoidable healthcare spend while delivering a more connected and personalized health experience for eligible employees. About Alight Solutions Alight is a leading benefits administration provider of health, wealth, leave and point solutions for many of the world's largest organizations and over 30 million people. Through the administration of employee benefits, Alight helps clients gain a benefits advantage while building a health and financially secure workforce by unifying the benefits ecosystem across health, wealth, wellbeing, absence management and navigation. Its Alight Worklife(R) platform empowers employers to gain a deeper understanding of their workforce and engage them throughout life's most important moments with personalized benefits management and data-driven insights, leading to increased employee wellbeing, engagement and productivity. Learn more at alight.com. About eMed eMed is the world's first end-to-end GLP-1 care platform built on Empathetic AI(TM). From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at www.eMed.com.

Fox Business
Jul 15th, 2026
Tom Brady joins eMed as chief wellness officer to expand employer-covered GLP-1 weight loss access

NFL legend Tom Brady has partnered with digital health company eMed as chief wellness officer to expand access to GLP-1 weight loss medications. The collaboration aims to incentivise employers to cover these drugs for eligible workers whilst reducing health insurance claims. Brady said the partnership addresses America's obesity epidemic by "democratising health and wellness in a way that the world has never seen". With more than 60% of Americans receiving health benefits through employers, eMed targets companies to provide coverage for GLP-1 medications. eMed CEO Linda Yaccarino called GLP-1 drugs a "pharmaceutical revolution", noting the programme combines AI, technology, and clinical support. The initiative offers both health benefits for employees and financial advantages for employers covering the medications.

MobiHealthNews
Jul 7th, 2026
Crux, eMed partner to expand employer access to GLP-1 medications.

Crux, eMed partner to expand employer access to GLP-1 medications. The collaboration aims to help employees access FDA-approved GLP-1s alongside clinical care, prescribing support, and payment and pharmacy fulfillment. Specialty employee benefits platform Crux announced a strategic collaboration with telehealth and digital health company eMed to improve employees' access to GLP-1 medications. Miami-based eMed, whose founding chief wellness officer is former NFL quarterback Tom Brady, offers an individual and employee health benefit platform that provides access to GLP-1 medications, at-home blood testing and a care package for common side effects of GLP-1s. Crux works with employers, individuals, brokers and consultants to offer benefits packages aimed at improving individuals' access to medication, including pharmacy fulfillment and home delivery. The partnership will combine eMed's clinical care model, including clinician evaluation and prescribing support, with Crux's payment and fulfillment infrastructure, which facilitates employers' tax-advantaged health reimbursement arrangement (HRA) contributions for employees, to help them access prescriptions, including FDA-approved GLP-1 medications. Members will have access to continuous clinical support through eMed, including dose adjustments, coaching and regular check-ins. "This partnership represents a pivotal step toward a future where healthcare is no longer reactive, but continuous, proactive and deeply personal," eMed CEO Linda Yaccarino said in a statement. "While GLP-1s are a powerful catalyst, they open the door to reimagining how clinical care, technology and benefits converge to drive better outcomes at scale. Together with Crux, we're enabling employers to lead that transformation while empowering people to take greater control of their health and their future." THE LARGER TREND Earlier this year, eMed closed a $200 million Series A funding round at a more than $2 billion valuation. In August 2025, the company's CEO, Yaccarino, joined eMed after serving for two years as CEO of Elon Musk-owned social media platform X, formerly Twitter. Prior to X, Yaccarino served as an NBCUniversal ad sales executive. A month later, X's former global head of strategic partners, Amy Elkins, joined eMed as chief operating officer. eMed announced a partnership with Arianna Huffington's behavioral-change technology platform, Thrive Global, to offer an end-to-end obesity-care program for employers. The offering combined eMed's clinical platform for GLP-1 and GIP medications with Thrive's behavior change and lifestyle offerings. eMed first launched in the fall of 2020 as a digital health company focused on at-home rapid COVID-19 testing through a collaboration with pharma giant Abbott. The company subsequently offered Urgent Care Telehealth Kits for at-home testing of COVID, influenza, strep throat and urinary tract infections, and has since pivoted to become a GLP-1-focused and AI-enabled weight-management platform.

Yahoo Finance
May 11th, 2026
Linda Yaccarino reflects on X transformation: 'I couldn't have been prouder

Linda Yaccarino, now CEO of telehealth company eMed, has reflected on her tenure leading Elon Musk's X, which ended in July 2025 after two years. She described the role as requiring conviction and comfort with being alone during a "massive global transformation under scrutiny". Yaccarino, who previously led global advertising at NBC Universal, was hired by Musk in May 2023 to stabilise the troubled social media platform. She credited her team with modernising business operations, expanding video features and digital wallet services, and bringing back advertisers. "I couldn't have been prouder," Yaccarino said, citing the company's financial stability and profitability. She joined eMed, a GLP-1 weight-loss medication and telehealth provider, in August 2025, applying her digital revenue expertise to healthcare.

Yahoo Finance
May 11th, 2026
Former X CEO Linda Yaccarino joins health tech firm valued at $2B to tackle chronic disease costs

Linda Yaccarino, former X CEO, has joined EMed Population Health as chief executive, leading the employer-focused GLP-1 medication provider now valued at over $2 billion following its latest funding round. The health tech company addresses rising corporate healthcare costs by providing access to GLP-1 medications, which have shown efficacy beyond diabetes and weight loss to treat chronic diseases. EMed works exclusively with FDA-approved medications from manufacturers including Novo Nordisk and Eli Lilly. The company claims its adherence programme delivers cost savings for employers by reducing hospitalisations and chronic disease claims. Despite being the most requested employee benefit, only one in five employers currently cover GLP-1 medications due to costs. Tom Brady recently joined as chief wellness officer and investor. The company plans global expansion beyond its current GLP-1 focus.